Commonwealth Equity Services LLC Has $6.81 Million Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Commonwealth Equity Services LLC decreased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 10.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 16,474 shares of the company's stock after selling 1,963 shares during the period. Commonwealth Equity Services LLC's holdings in IDEXX Laboratories were worth $6,811,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Flossbach Von Storch SE raised its stake in shares of IDEXX Laboratories by 5,439.3% during the fourth quarter. Flossbach Von Storch SE now owns 473,336 shares of the company's stock valued at $195,696,000 after acquiring an additional 464,791 shares in the last quarter. Assenagon Asset Management S.A. increased its position in shares of IDEXX Laboratories by 265.6% in the 4th quarter. Assenagon Asset Management S.A. now owns 435,049 shares of the company's stock valued at $179,867,000 after acquiring an additional 316,048 shares during the period. Seilern Investment Management Ltd purchased a new position in IDEXX Laboratories during the 4th quarter worth approximately $113,104,000. Vontobel Holding Ltd. lifted its holdings in shares of IDEXX Laboratories by 90.1% in the 4th quarter. Vontobel Holding Ltd. now owns 418,563 shares of the company's stock valued at $173,051,000 after buying an additional 198,404 shares during the period. Finally, Raymond James Financial Inc. acquired a new stake in IDEXX Laboratories during the fourth quarter valued at $71,893,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on IDXX. Leerink Partners began coverage on IDEXX Laboratories in a report on Monday, December 2nd. They issued an "outperform" rating and a $500.00 price objective on the stock. Bank of America raised their price objective on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a report on Tuesday, February 4th. Leerink Partnrs upgraded shares of IDEXX Laboratories to a "strong-buy" rating in a research report on Monday, December 2nd. Morgan Stanley lowered their target price on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a report on Wednesday, January 29th. Finally, Barclays upped their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a report on Tuesday, February 4th. Four equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $533.75.

IDEXX Laboratories Stock Up 0.0 %

IDXX traded up $0.05 during midday trading on Wednesday, hitting $417.71. 760,693 shares of the company's stock traded hands, compared to its average volume of 555,046. IDEXX Laboratories, Inc. has a one year low of $398.50 and a one year high of $548.88. The stock's fifty day simple moving average is $437.36 and its 200-day simple moving average is $444.05. The company has a market cap of $33.86 billion, a PE ratio of 39.15, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95.

Insider Activity

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of the firm's stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the sale, the director now owns 3,061 shares of the company's stock, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP George Fennell sold 9,986 shares of the company's stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the transaction, the executive vice president now owns 8,176 shares of the company's stock, valued at approximately $3,781,645.28. This trade represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 2.11% of the company's stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.